Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Mar 14;104(11):e41853.
doi: 10.1097/MD.0000000000041853.

Clinical characteristics and treatment patterns of patients with gastroenteropancreatic neuroendocrine neoplasia in Germany receiving peptide receptor radionuclide therapy: A real-world data registry-based study

Affiliations
Observational Study

Clinical characteristics and treatment patterns of patients with gastroenteropancreatic neuroendocrine neoplasia in Germany receiving peptide receptor radionuclide therapy: A real-world data registry-based study

Claus von Hessert-Vaudoncourt et al. Medicine (Baltimore). .

Abstract

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare malignancies deriving from the endocrine system in the gastrointestinal tract including the pancreas. Prognosis is greatly heterogenous due to its dependency on various factors, most importantly stage and differentiation. Several studies report an alarming rise in incidence in the past decade. Despite there being some therapeutical options, best therapy sequence still needs to be defined, particularly for unresectable and/or intermediate and high-grade NENs. Peptide receptor radionuclide therapy (PRRT) was approved in Europe and USA in 2017 and 2018, respectively. Studies with real-world systematic data on characteristics and treatment patterns of PRRT-receiving patients was non-existent at the time of this writing. In this retrospective study, we identified within the German NET-Registry 203 patients diagnosed with GEP-NEN having received PRRT from 1995 to 2023. We assessed general clinical patient characteristics, disease-specific characteristics, treatments and outcomes. To obtain a more up-to-date picture of treatment modalities and outcomes, a subgroup of the study population was allocated to the "therapy cohort," defined by patients with date of first diagnosis between 2010 and 2023 (open cohort). Mean age of the study population was 58 years (SD 12 years) with 51.7% being men. Most patients had a WHO performance score of 0 to 1 (41.4% and 50.5%, respectively). Most NEN cases were of small intestine/pancreatic origin (46.3% and 45.3%, respectively) and displayed well/moderate differentiation (55.3%). Ki-67 was generally within the 3% to 20% range (57.92%). Most patients presented with metastasis at diagnosis (73.9%). Somatostatin analogs (SSAs), chemotherapy and surgery were the most common non-PRRT therapy options (65.3%, 60.2%, and 50.0%, respectively). PRRT was most often applied as third- or second-line therapy (42.3% and 36.6%, respectively), usually after surgery and/or SSA treatment. As PRRT had been administered using different regimens, tumor response evaluation showed mixed responses. Given the low sample size and considerable amount of missing response data, no correlation analysis between PRRT sequencing and tumor response could be performed. Overall, the clinical characteristics and treatment patterns tend to follow trends observed in other studies or medical guidelines. Finally, this study presents real-world data that more accurately describes GEP-NEN disease in Germany and treatment modalities after PRRT's approval.

Trial registration: ClinicalTrials.gov NCT06016855.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Distribution of study population by age and sex (1995–2023). n = 203 patients diagnosed with GEP-NEN. No significant difference was found between the ages of men and women (P value = .70). The mean of men minus women = −0.65. 95% confidence interval of this difference: from −4.02 to 2.71. GEP-NEN = gastroenteropancreatic-neuroendocrine neoplasia.
Figure 2.
Figure 2.
Distribution of the therapy cohort by age and sex (2010–2023). n = 98 patients diagnosed with GEP-NEN. No significant difference was found between the ages of men and women (P value = .83). The mean of men minus women = −0.55. 95% confidence interval of this difference: from −4.61 to 5.71. GEP-NEN = gastroenteropancreatic-neuroendocrine neoplasia.
Figure 3.
Figure 3.
Boxplot showing the time to failure of strategy of peptide receptor radionuclide therapy in the therapy cohort (2010–2023), according to line of therapy. Median time to strategy failure is illustrated. First-line PRRT: 325.5 days (IQR: 172–958); second-line PRRT: 376 days (IQR: 190.6–1228.5); third-line PRRT: 276 days (IQR: 84–598); fourth-line PRRT: 742.5 (IQR: 172.5–1400). No significant difference was found between the groups (P = .49). IQR = interquartile range, PRRT = peptide receptor radionuclide therapy.

References

    1. Pavel M, Öberg K, Falconi M, et al. .; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844–60. - PubMed
    1. Nagtegaal ID, Odze RD, Klimstra D, et al. .; WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–8. - PMC - PubMed
    1. Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep. 2021;23:43. - PMC - PubMed
    1. Grundmann N, Voigtländer S, Hakimhashemi A, Pape UF, Meyer M, Müller-Nordhorn J. Site-specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany. Cancer Med. 2023;12:19949–58. - PMC - PubMed
    1. Rindi G, Falconi M, Klersy C, et al. . TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. 2012;104:764–77. - PubMed

Publication types

MeSH terms

Supplementary concepts

Associated data